Benefits of Liraglutide Treatment in Overweight and Obese Older Individuals With Prediabetes

The aim was to evaluate the ability of liraglutide to augment weight loss and improve insulin resistance, cardiovascular disease (CVD) risk factors, and inflammation in a high-risk population for type 2 diabetes (T2DM) and CVD. We randomized 68 older individuals (mean age, 58±8 years) with overweigh...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes care 2013-10, Vol.36 (10), p.3276-3282
Hauptverfasser:	KIM, Sun H, ABBASI, Fahim, IDA, Yii-Der, REAVEN, Gerald, LAMENDOLA, Cindy, LIU, Alice, ARIEL, Danit, SCHAAF, Patricia, GROVE, Kaylene, TOMASSO, Vanessa, OCHOA, Hector, LIU, Yeheng V
Format:	Artikel
Sprache:	eng
Schlagworte:	Biological and medical sciences Body Weight - drug effects Caloric Restriction Cardiovascular disease Care and treatment Diabetes Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - drug therapy Diabetes. Impaired glucose tolerance Diseases Double-Blind Method Drug therapy Endocrine pancreas. Apud cells (diseases) Endocrinopathies Female Glucagon-Like Peptide 1 - analogs & derivatives Glucagon-Like Peptide 1 - therapeutic use Glucose Health aspects Humans Hypoglycemic Agents - therapeutic use Insulin resistance Insulin Resistance - physiology Liraglutide Male Medical sciences Metabolic diseases Middle Aged Obesity Obesity - blood Obesity - drug therapy Original Research Overweight - blood Overweight - drug therapy Overweight persons Prediabetic state Prediabetic State - blood Prediabetic State - drug therapy Prognosis Risk factors Triglycerides - blood Weight control Weight Loss - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!